Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue from contracts with customers (Details)

v3.23.2
Revenue - Revenue from contracts with customers (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
contract
Mar. 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
contract
Jun. 30, 2023
USD ($)
contract
Jun. 30, 2022
USD ($)
contract
Dec. 31, 2022
USD ($)
Revenue            
Revenue $ 5,130,000   $ 5,538,000 $ 52,731,000 $ 9,113,000  
Number of contracts with customers | contract 2   3 3 3  
Deferred revenue decrease           $ 35,737,000
Deferred revenue   $ 148,675,000       $ 184,412,000
Upfront payment by GSK for Termination and Transfer Agreement   9,613,000        
Amount of increase in deferred income caused by the change in the exchange rate   $ 5,890,000        
Exchange rate 1.26     1.26   1.21
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements $ 318,107,000     $ 318,107,000    
Revenue recognized in the period       52,046,000    
Development revenue            
Revenue            
Revenue $ 5,130,000   $ 5,538,000 $ 52,731,000 $ 9,113,000